Eton Pharmaceuticals, Inc. (ETON) — Analyst outlook / Analyst consensus target is. Based on 6 analyst ratings, the consensus is bullish — 6 Buy.
The consensus price target is $25.00 (low: $15.00, high: $35.00), representing a downside of 7.8% from the current price $27.12.
Analysts estimate Earnings Per Share (EPS) of $-0.13 and revenue of $0.04B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.15 vs est $-0.13 (missed -18.4%). 2025: actual $-0.17 vs est $0.37 (missed -145.9%). Analyst accuracy: 0%.
ETON Stock — 12-Month Price Forecast
$25.00
▼ -7.82% Downside
Average Price Target
Based on 6 Wall Street analysts offering 12-month price targets for Eton Pharmaceuticals, Inc., the average price target is $25.00, with a high forecast of $35.00, and a low forecast of $15.00.
The average price target represents a -7.82% change from the last price of $27.12.
Highest Price Target
$35.00
Average Price Target
$25.00
Lowest Price Target
$15.00
ETON Analyst Ratings
Buy
Based on 6 analysts giving stock ratings to Eton Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — ETON
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.15
vs Est –$0.13
▼ 15.6% off
2025
Actual –$0.17
vs Est $0.37
▼ 317.6% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — ETON
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.039B
vs Est $0.038B
▲ 2.8% off
2025
Actual $0.080B
vs Est $0.079B
▲ 0.9% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
